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Abstract
Objective—To estimate the incidence of first hip or clinical vertebral fracture or major 
osteoporotic (hip, clinical vertebral, proximal humerus or wrist) fracture in postmenopausal 
women receiving their first bone mineral density (BMD) test before age 65.
Methods—We studied 4068 postmenopausal women aged 50 to 64 without hip or clinical 
vertebral fracture or antifracture treatment at baseline, participating in the Women's Health 
Initiative BMD cohort study. BMD tests were performed between October 1993 and April 2005, 
with fracture follow-up through 2012. The outcomes were the times for 1% of women to sustain a 
hip or clinical vertebral fracture, and for 3% to sustain a major osteoporotic fracture before 
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initiating treatment, adjusting for clinical risk factors and accounting for competing risks. Women 
without and with osteoporosis on their first BMD test were analyzed separately.
Results—During a maximum 11.2 years of concurrent BMD and fracture follow-up, the adjusted 
estimated time for 1% of women to have a hip or clinical vertebral fracture was 12.8 years (95% 
CI, 8.0, 20.4) for aged 50 to 54 and 7.6 years (95% CI, 4.8 to 12.1) for aged 60 to 64 for those 
without baseline osteoporosis, and 3.0 years (95% CI, 1.3, 7.1) for all women aged 50 to 64 with 
baseline osteoporosis. Results were similar for major osteoporotic fracture.
Conclusion—Due to very low rates of major osteoporotic fracture, postmenopausal women age 
50 and 64 without osteoporosis on a first BMD test are unlikely to benefit from frequent 
rescreening before age 65.
Keywords
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Introduction
While routine bone mineral density (BMD) screening is universally recommended for 
women aged 65 years and older,1-8 the optimal schedule for BMD screening in younger 
(aged 50 to 64) postmenopausal women is unknown. Four percent of US women aged 50-59 
and 20% of women aged 60-69 were reported to have osteoporosis (very low BMD) in 
1995,9 and the overall prevalence of osteoporosis in women aged 50 and older decreased by 
2006.10 Because of these low prevalence rates, identification of osteoporosis in younger 
postmenopausal women is challenging. Clinical practice guidelines typically encourage 
BMD screening in postmenopausal women under age 65 according to their risk factors for 
fracture,2, 3 but there is no agreement regarding which factors to choose from lists of up to 
90 predictors. Unlike most clinical screening guidelines for chronic diseases, BMD 
screening guidelines do not specify a standard testing interval. Younger postmenopausal 
women without extra risk factors for BMD loss may question whether routine (repeated) 
BMD testing should be performed soon after the onset of menopause, or whether this test 
can safely be deferred.11 Age-defined data are essential for younger postmenopausal women 
and their primary care providers to use in shared decision making regarding the timing of 
BMD tests.
For women over age 65, the estimated time-to-osteoporosis is a useful metric to decide a 
BMD screening interval because of known significant fracture rates in this age range of 
women.12 In contrast, time-to-fracture estimates must inform the frequency of BMD 
screening in younger postmenopausal women because their fracture rates may be low 
despite transitory accelerated BMD loss immediately after the onset of menopause.13 In 
women aged 50 to 54, the estimated 5-year risk is 0.2% for first spine fracture and 0.0% for 
first hip fracture, compared to 1.5% and 0.8% for the respective risks in women aged 65 to 
69.14 At the same time, a large study of postmenopausal women followed for up to 3 years 
after baseline peripheral (heel, forearm, or finger) BMD measures found that relative risks 
for fracture were similar in women aged 50 to 59 compared to older age groups.15 To 
thoroughly examine the clinical utility of BMD screening in younger postmenopausal 
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women, those without and with osteoporosis must be studied, with adequate follow-up to 
estimate fracture incidence before age 65 (when routine BMD testing is recommended).
To characterize the incidence of hip or clinical vertebral fracture in younger postmenopausal 
women at any baseline BMD level, we conducted competing risk analyses of 4068 
postmenopausal women aged 50 to 64 years without a history of hip or clinical vertebral 
fracture or treatment for osteoporosis, followed longitudinally for up to 11 years in the 
Women's Health Initiative bone density cohort. We hypothesized that younger 
postmenopausal women without osteoporosis (hip and lumbar spine T-scores >-2.50) at 
baseline would be unlikely to experience a hip or clinical vertebral fracture or other major 
osteoporotic fracture before age 65.
Methods
Study participants
We studied 4068 postmenopausal women aged 50 to 64 years at baseline participating in the 
Women's Health Initiative Observational Study (WHI-OS) or Clinical Trials (CT, Hormone 
Therapy, Calcium/vitamin D and Dietary Trials) placebo groups who had at least one DXA 
scan between October 1993 and April 2005 at the Tucson/Phoenix, Pittsburgh or 
Birmingham clinical centers. BMD was followed for a maximum of 11.2 years, and fracture 
was followed for a maximum of 18.6 years in the analytical cohort as a whole. Because the 
competing risk framework requires concurrent follow-up of the primary endpoint (hip or 
clinical vertebral fracture) and competing risks (including BMD measurements), the 
effective maximum length of follow-up for the analyses of time to fracture was 11.2 years. 
However, data from the full period of fracture follow-up (18.6 years) were tabulated in a 
separate analysis.
Women with any BMD T-score at baseline (including osteoporosis) were included in the 
competing risk analyses. Details of the study examinations and selection of the analytical 
cohort are described in the Supplemental Digital Content and Figure 1. The study protocol 
and consent forms for the WHI study were approved by the institutional review boards for 
all participating institutions. The analysis protocol was reviewed and approved by the 
Institutional Review Board of the University of North Carolina.
BMD classifications and definition of osteoporosis
Eligible participants had DXA BMD measurements at the femoral neck, total hip and 
lumbar spine at one or more study examinations. World Health Organization diagnostic 
criteria16 for osteoporosis were used to classify participants by their baseline BMD T-scores 
([BMD of participant – mean BMD of reference population]/SD of BMD of reference 
population) at the femoral neck, total hip or lumbar spine. T-scores were calculated using 
National Health and Nutrition Examination Study III BMD norms for non-Hispanic white 
women aged 20-29.17, 18 Data from participants without (T score at femoral neck, total hip, 
and lumbar spine > -2.50) and with osteoporosis (lowest T-score <= -2.50) were analyzed 
separately. We emphasized BMD screening in this study because numerous randomized 
trials19-22 have demonstrated the benefit of pharmacologic treatment in postmenopausal 
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women who have osteoporosis as defined by BMD criteria, and because the US Preventive 
Services Task Force1, 23 has rigorously reviewed the magnitude of benefits, harms, and net 
benefit of the use of DXA BMD screening in postmenopausal women.
Outcomes
The primary outcome was the estimated time interval for 1% of participants in three age 
groups to transition from the baseline T-score categories to hip or clinical vertebral fracture 
before developing osteoporosis (for those without osteoporosis at baseline), before initiating 
treatment for osteoporosis, and prior to dying. The secondary outcome was the time for 3% 
of women in each age group to have a major osteoporotic fracture (includes hip, clinical 
spine, proximal humerus, or wrist fracture according to the World Health Organization 
definition24).
Fractures were verified by review of radiology, magnetic resonance imaging, or operative 
reports by centrally trained physician adjudicators at each of the BMD clinics participating 
in WHI. For fracture sites other than hip, local clinic physician-adjudicated fractures were 
used. Final adjudication of hip fractures was performed centrally by blinded WHI physician 
adjudicators. The agreement between central and local adjudication for hip fracture was 
94%. Additional details regarding fracture adjudication are included in the Supplemental 
Digital Content.
Independent variables
Demographics and prevalence of risk factors for osteoporosis and fracture were tabulated. 
The regression models for occurrence of fracture for women without osteoporosis at 
baseline were adjusted for baseline age group (50-54, 55-59, 60-64), continuous T-score 
(centered at mean of lowest T-score at any site for each individual without osteoporosis at 
baseline), body mass index (BMI), race/ethnicity (black [referent] vs. non-black-non-white 
vs. white) and current hormone therapy use status at baseline. The regression model for 
women with osteoporosis at baseline was adjusted only for age (centered at mean age of 
women with baseline osteoporosis).
Medication use
Use of Food and Drug Administration–approved agents for the treatment of osteoporosis 
(bisphosphonates including alendronate, risedronate, pamidronate or zoledronate; calcitonin; 
raloxifene; parathyroid hormone) was assessed in the WHI Observational Study and WHI 
Extension Hormone Use Update medication follow-up surveys (see Supplemental Digital 
Content for survey questions). Osteoporosis treatment agents were prescribed by the 
participant's doctor(s), not by WHI study personnel. Participants were asked to report any 
use of the individual agents in the past year. The exact length of therapy was unknown.
Statistical analysis
Competing risk analyses were conducted to estimate the cumulative incidence functions for 
each age group for the time to the development of a hip or clinical vertebral fracture, and the 
corresponding intervals for 1% of participants to make the transition to fracture. The 
competing risks were development of osteoporosis (for women without osteoporosis at 
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baseline), initiation of a Food and Drug Administration–approved agent for the treatment of 
osteoporosis, and death. The time origin was the first study visit including BMD 
measurements at all three anatomical sites (femoral neck, total hip, lumbar spine), with 
follow-up continuing until the study examination preceding death or drop-out. Parametric 
regression models25 were fit to the cumulative incidence of fracture using naïve maximum 
likelihood analysis. The 1% time intervals and associated confidence intervals were based 
on the competing risks quantile methodology,26 as implemented for parametric models by 
Lee and Fine.27 Similar competing risk models were constructed to estimate the time for 3% 
of women in each age group to have a major osteoporotic fracture. Technical details are 
provided in the Supplemental Digital Content.
The very small number of major fracture events precluded use of competing risk regression 
analysis to estimate time to fracture adjusting for additional clinical risk factors beyond 
those listed above. We instead used Fisher's exact test to compare the crude number of 
participants without and with osteoporosis at baseline who had a hip or clinical vertebral 
fracture after their baseline visit, cross-tabulated with key categorical risk factors described 
in the independent variables section. Because concurrent BMD and fracture follow-up was 
not required, we used the full amount of fracture follow-up data (over a maximum of 18.6 
years) and included all hip and clinical vertebral fractures, whether or not they occurred 
before a competing risk. For this reason, the total number of fractures was greater in the 
Fisher's exact test analysis compared to the competing risk analyses.
All analyses were performed using Statistical Analysis Software (SAS) 9.3.28
Results
Characteristics of the analytical cohort
Baseline characteristics of the analytical cohort are shown in Table 1. Tabulations of 
osteoporosis according to three different definitions (Table A1 and Supplement Tables A2-
A3) revealed that 51% (170/344) of the osteoporosis diagnoses were determined by the 
lumbar spine BMD measurement (lumbar spine T-score <=-2.50, femoral neck and total hip 
T-score >-2.50).
Estimated time to hip or clinical vertebral fracture
The following proportions of women (including those with osteoporosis at baseline) 
sustained a hip or clinical vertebral fracture before initiating osteoporosis treatment: aged 50 
to 54 at baseline, 12/1069 (1.1%); aged 55 to 59 at baseline, 24/1391 (1.7%); aged 60 to 64 
at baseline, 37/1608 (2.3%); all ages 73/4068 (1.8%).
Unadjusted (Fig. 2) and covariate-adjusted estimates of the cumulative incidence of first hip 
or clinical vertebral fracture as a function of testing interval length were similar. The 
adjusted estimated times for 1% of women without osteoporosis to transition to hip or 
clinical vertebral fracture decreased with increasing age (Table 2), ranging from 12.8 years 
(95% CI, 8.0, 20.4) for aged 50 to 54, to 11.7 years (95% CI, 6.9, 20.0) for aged 55 to 59, to 
7.6 years (95% CI, 4.8, 12.1) for aged 60 to 64. For those with osteoporosis, the age-
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adjusted time interval was 3.0 years (95% CI, 1.3, 7.1) for women aged 50 to 64 analyzed 
together.
The crude proportion (not accounting for competing risks) of participants that had at least 
one hip or clinical vertebral fracture by the end of follow-up was significantly higher for 
women with osteoporosis compared to women without osteoporosis at baseline in all 
subgroups of age, BMI, personal fracture history, parental history of hip fracture, smoking 
and hormone therapy use (Table 3). Tabulations of primary endpoint and competing risk 
events (Table A1) showed that treatment was the first event for 673 women (16.5% of the 
analytical cohort), i.e., 531 (13.1% of the analytical cohort) participants without 
osteoporosis at baseline were treated before they developed osteoporosis or had a hip or 
clinical vertebral fracture, and 142 (3.5% of the analytical cohort) women with baseline 
osteoporosis were treated before they had a hip or clinical vertebral fracture.
Estimated time to major osteoporotic fracture
These proportions of women (including those with osteoporosis at baseline) sustained a 
major osteoporotic fracture before initiating osteoporosis treatment: aged 50 to 54 at 
baseline, 38/1069 (3.6%); aged 55 to 59 at baseline, 71/1391 (5.1%); aged 60 to 64 at 
baseline, 93/1608 (5.8%); all ages, 202/4068 (5.0%).
The estimated times for 3% of women without baseline osteoporosis to have a major 
osteoporotic fracture (hip, clinical spine, proximal humerus, or wrist) ranged from 11.5 
years (95% CI, 8.0, 16.7) for women aged 50 to 54, to 8.6 years (95% CI, 5.8, 12.8) for 
women aged 60 to 64 at baseline (Table 4).
For all women aged 50 to 64 with baseline osteoporosis analyzed together, the age-adjusted 
time for 3% to have a major osteoporotic fracture was 2.5 years (95% CI, 1.2, 5.3; event N 
31/344, 9.0%). The proportions of women with baseline osteoporosis who had a major 
osteoporotic fracture before initiating treatment were: 3/40 (7.5%) for age 50 to 54; 10/106 
(9.43%) for age 55 to 59; 18/198 (9.1%) for age 60 to 64. Within these groups, 3, 7 and 9 
women respectively had a major osteoporotic fracture before age 65.
Discussion
This longitudinal study found that among postmenopausal women aged 50 to 64 without 
osteoporosis on their first BMD test, less than 1% experienced a hip or clinical vertebral 
fracture and less than 3% experienced a major osteoporotic fracture by 7 years. The analysis 
accounted for different clinical trajectories, i.e., incident osteoporosis, death or initiation of 
treatment before a first major osteoporotic fracture was modeled as a competing risk. Our 
results suggest that younger postmenopausal women without osteoporosis on their first 
BMD scan are unlikely to benefit from frequent rescreening before age 65. Adjustment for 
several clinical risk factors for fracture did not substantially alter these findings. Women 
with osteoporosis on their first BMD test (8.5% of cohort) had a significantly higher risk of 
fracture before age 65 compared to women without osteoporosis.
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Empirical data on age-appropriate osteoporosis screening are important because of 
substantial underutilization of BMD testing in women aged 65 and older,29 and 
inappropriate use in other postmenopausal women who do not meet screening criteria in 
published clinical practice guidelines.30 In 2011, the National Physicians Alliance initiated a 
project titled “Promoting Good Stewardship in Clinical Practice” that aimed to develop a list 
of the top 5 activities in family medicine, internal medicine, and pediatrics where the quality 
of care could be improved.31 This list included the recommendation, “don't use DEXA 
screening for osteoporosis in women under age 65 years or men under 70 years with no risk 
factors,” citing the lack of cost-effectiveness in these groups. While the project's focus on 
cost control was understandable, the BMD testing recommendations were not based on 
original studies testing this hypothesis. Our results substantiate that DXA BMD testing has a 
lower yield for younger postmenopausal women compared to women age 65 and older. 
However, because hip and spine fractures would be catastrophic for working adult women 
who are otherwise healthy, we do not interpret our results to mean that no postmenopausal 
women under age 65 should have a DXA test. Instead, the data suggest that before age 65, 
postmenopausal women would be unlikely to have a major fracture, but development of 
osteoporosis by BMD criteria remains important because it confers higher immediate risk of 
major fracture compared to greater BMD levels. Our results are generalizable to younger 
postmenopausal women with good general health who are candidates for BMD screening in 
a primary care practice. Our results should not be applied to patients with existing fragility 
fracture or secondary causes of osteoporosis who are seen in subspecialty clinics, or to 
patients who have taken anti-fracture treatment agents. Those individuals are no longer 
candidates for screening because they have higher baseline risk for subsequent fractures, and 
thereby different testing and treatment criteria.
Current clinical practice guidelines encourage the use of risk factors for fracture to select 
postmenopausal women under age 65 who are good candidates for DXA testing.1, 2 Two 
analyses of large cohorts of postmenopausal women aged 50 to 64 at baseline suggest that 
simple fracture risk assessment tools (including one calculated from age and weight) 
perform as well as more complicated tools for this purpose.32, 33 Our data can help inform a 
BMD testing interval for postmenopausal women who are screened before age 65. Using the 
more conservative time estimates for major osteoporotic fracture, clinicians might allow 
women aged 50 and 54 without osteoporosis on their first BMD test to wait 10 years for 
their next test. Similarly, women aged 60 to 64 without osteoporosis on their first BMD test 
might wait until after age 65 for their next test. Other approaches have been considered, e.g. 
Reid and Gamble's 2014 modeling study based on the doubling time for predicted hip 
fracture risk suggested that a BMD screening interval of 5 to 6 years may be appropriate for 
many intermediate-risk women aged 65 and older.34 This 5-to-6-year interval might be 
interpreted as a conservative estimate for intermediate-risk younger postmenopausal women.
Women found to have osteoporosis in this age range are no longer candidates for a routine 
screening schedule. We included these women in the analysis because if they had 
osteoporosis but did not sustain a fracture until well after age 65, the value of any BMD 
screening before age 65 would be questioned. Instead, we found that all (3/3) of the women 
aged 50 to 54 and over half (16/28) of those aged 55 to 64 with baseline osteoporosis who 
had a major osteoporotic fracture during follow-up had the fracture before age 65. This 
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suggests that clinicians should promptly counsel younger postmenopausal women with 
osteoporosis regarding the benefits and harms of treatment, rather than assuming this 
discussion can be deferred. Although women with osteoporosis had a substantially higher 
risk of fracture, most of the hip and clinical vertebral fractures in the cohort as a whole 
occurred in women with baseline T-scores >-2.50 (i.e., 65 of 3724 [1.7%] women with 
baseline T-scores >-2.50 vs. 25 of 344 [7.3%] women with baseline T-scores <=-2.50 had a 
hip or clinical vertebral fracture). These results are consistent with other longitudinal studies 
of postmenopausal women,35, 36 and they demonstrate that BMD testing cannot identify 
every individual who will have a future fragility fracture. Such findings emphasize the 
importance of further investigations of risk factor assessment and screening methods to 
identify poor bone quality that also contributes to increased fracture risk.
According to current clinical practice guidelines,2, 5, 8 women with asymptomatic 
radiographic vertebral fractures should also receive osteoporosis treatment, regardless of 
BMD T-score level. Radiographic vertebral fracture data were not available in the WHI 
study, but a US population-based study reported very low vertebral fracture incidence rates 
for this age range of women (215-349 per 100,000 [0.35%] for women aged 50 to 64).37 
Considering that one-third or fewer of incident radiographically identified vertebral fractures 
are clinically diagnosed, clinicians may consider additional imaging (lateral thoracic and 
lumbar spine radiographs or densitometric vertebral fracture assessment imaging) in 
postmenopausal women with BMD T-scores between -1.5 and -2.4 who have height loss or 
other risk factors that may suggest prevalent radiographic vertebral fracture.38
The low incidence rates of hip or clinical vertebral fractures in our analysis are consistent 
with the 2008 Cochrane review of alendronate treatment that showed very low absolute risk 
reductions (ARR) for hip and clinical vertebral fractures in younger postmenopausal 
women. Women aged 50 to 54 treated with alendronate had 5-year ARR of 0.1% for first 
spine fracture and 0.0% for first hip fracture, with analogous figures of 0.5% and 0.1% for 
women aged 60 to 64, and 0.7% and 0.4% for women aged 65 to 69.39 In contrast, the ARR 
for alendronate-treated women aged 90 and older was 11.1% for spine fracture and 2.1% for 
hip fracture. The very low treatment efficacy of alendronate in the younger women was 
likely due to their low baseline (untreated) fracture rates, so that treatments did not confer 
significant absolute fracture risk reduction. Because of these low fracture rates, BMD 
screening and treatment in younger postmenopausal women is likely to have less of an 
impact on the population burden of fracture compared to screening and treatment in women 
aged 65 and older. Careful selection of women for screening and treatment is especially 
important before age 65 because the risk of complications such as atypical femoral 
fractures40 and osteonecrosis of the jaw41 appears to rise with increasing duration of 
exposure to bisphosphonates. The 3% fracture threshold used in our analysis of major 
osteoporotic fractures was much lower than the 20% estimated fracture risk threshold for 
which treatment may be recommended according to the WHO FRAX fracture risk 
algorithm.24 Thus, our time estimates for the major osteoporotic fracture endpoint should 
not be viewed as an estimated time until treatment initiation.
Our study had several limitations. Our time estimates were based only on transitions to 
major fracture; the full benefits and risks of screening and cost-effectiveness were not 
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considered. The analysis had inadequate power to study fracture risk in subgroups defined 
by individual risk factors. For example, a higher proportion of women with osteoporosis and 
current hormone therapy use at baseline had a hip or clinical vertebral fracture during 
follow-up compared to women with osteoporosis and without current hormone therapy use 
at baseline. This might have represented confounding by treatment indication or mere 
variability in an estimate based on very few fracture events. Over 97 percent of the original 
WHI participants were not eligible for this analysis because they were not part of the BMD 
cohort. However, our study population included 89.9% (4068/4527) of the WHI participants 
with technically adequate BMD measurements at one or more study examinations. Seventy-
four percent of our sample comprised white women, and 15 percent comprised black 
women; because the prevalence of hip osteoporosis in white women is lower than the 
prevalence in African American women by NHANES estimates,10 our calculated estimates 
of time to major fracture are likely to be a reasonable estimate for women of all races. 
Because of rare fracture events for the lowest-risk women, some of our time estimates were 
extrapolations with wide confidence intervals. Strengths of the analysis include the large 
size of the cohort and the long follow-up period involving repeated BMD testing, fracture 
ascertainment between study visits, inclusion of the lumbar spine site in the BMD 
measurements and inclusion of mortality as a competing risk.
Conclusions
In conclusion, postmenopausal women aged 50 to 64 without osteoporosis on their first 
BMD test were very unlikely to have a major osteoporotic fracture before age 65. Although 
less than 10% of our cohort had osteoporosis at baseline, the osteoporosis subgroup had a 
significantly higher immediate risk of major fracture. Screening frequency should be based 
on age and baseline T-score to maximize the clinical utility of BMD testing in this age 
range.
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Figure 1. Study population for analyses of time to hip or clinical vertebral fracture
Of the 4527 women who had DXA bone mineral density (BMD) testing, 459 were excluded, 
including those who had a past hip or clinical vertebral fracture or osteoporosis treatment 
(bisphosphonate or calcitonin) at their first study examination, or who did not have BMD 
measurements at two or more examinations, or one BMD measurement and subsequent 
development of a competing risk. In the analytical cohort of 4068 women with adequate 
femoral neck, total hip, and lumbar spine BMD measurements prior to censoring, two 
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transitions were studied: T-score >-2.50 to first hip or clinical vertebral fracture (N=3724), 
and T-score <=-2.50 to first hip or clinical vertebral fracture (N=344).
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Figure 2. Unadjusted cumulative incidence of hip or clinical vertebral fracture according to 
baseline age range
The proportion of women who had transitioned to first hip or clinical vertebral fracture is 
plotted as a function of time. The cumulative incidence curves are estimated by parametric 
cumulative incidence models for known fracture dates. The dotted horizontal line shows 
where 1% of women have transitioned to first hip or clinical vertebral fracture; where this 
line intersects with each cumulative incidence curve, a vertical line to the x-axis marks the 
estimated time interval.
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Table 1
Baseline characteristics and follow-up time of the women studied to determine time to 
major fracture
Characteristics at baseline Number (%) or Mean (SD)






 50-54 1029 (27.6) 40 (11.6) 1069 (26.3)
 55-59 1285 (34.5) 106 (30.8) 1391 (34.2)
 60-64 1410 (37.9) 198 (57.6) 1608 (39.5)
BMIb
 <25 1202 (32.3) 215 (62.5) 1417 (34.8)
 ≥25 2522 (67.7) 129 (37.5) 2651 (65.2)
Race no./ total no. (%)
 White (non-Hispanic) 2729/3717 (73.4) 286/344 (83.1) 3015/4061 (74.2)
 African American 587/3717 (15.8) 19/344 (5.5) 606/4061 (14.9)
 Asian 16/3717 (0.4) 3/344 (0.9) 19/4061 (0.5)
 Hispanic 307/3717 (8.3) 28/344 (8.1) 335/4061 (8.3)
 Other 78/3717 (2.1) 8/344 (2.3) 86/4061 (2.1)
Years of education no./ total no. (%)
 Less than high school 260/3692 (7.0) 29/342 (8.5) 289/4034 (7.2)
 High school/some college 2176/3692 (58.9) 195/342 (57.0) 2371/4034 (58.8)
 College/some graduate school 641/3692 (17.4) 68/342 (19.9) 709/4034 (17.6)
 Completed graduate school 615/3692 (16.7) 50/342 (14.6) 665/4034 (16.5)
Previous fracture after age 55 no./ total no. (%)
 Yes 193/2253 (8.57) 37/230 (15.5) 230/2491 (9.2)
 No 2060/2253 (91.4) 201/230 (84.5) 2261/2491 (90.8)
Hormone therapy use no./ total no. (%)
 Yes 463/3641 (12.7) 52/332 (15.7) 515/3973 (13.0)
 Past 1806/3641 (49.6) 95/332 (28.6) 1901/3973 (47.8)
 Never 1372/3641 (37.7) 185/332 (55.7) 1557/3973 (39.2)
Current smoker no./ total no. (%)
 Current 244/3701 (6.6) 28/342 (8.2) 272/4043 (6.7)
 Past 1413/3701 (38.2) 117/342 (34.2) 1530/4043 (37.8)
 Never 2044/3701 (55.2) 197/342 (57.6) 2241/4043 (55.4)
Alcohol consumption (drinks per week) no./ total no. (%)
 0 drinks per week 579/3693 (15.7) 63/343 (18.4) 642/4036 (15.9)
 <1 drinks per week 1259/3693 (34.1) 120/343 (35.0) 1379/4036 (34.2)
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Characteristics at baseline Number (%) or Mean (SD)





 1 to 6 drinks per week 784/3693 (21.2) 60/343 (17.5) 844/4036 (20.9)
 ≥7 drinks per week 275/3693 (7.5) 23/343 (6.7) 298/4036 (7.4)
 Past drinker 796/3693 (21.6) 77/343 (22.4) 873/4036 (21.6)
History of parent with hip fracture
 Yes 825 (22.2) 101 (29.4) 926 (22.8)
 No 2899 (77.8) 243 (70.6) 3142 (77.2)
Rheumatoid arthritis no./ total no. (%)
 Yes 155/3722 (4.2) 18/344 (5.23) 173/4066 (4.3)
 No 3567/3722 (95.8) 326/344 (94.8) 3893/4066 (95.7)
Current oral glucocorticoid use
 Yes 96 (2.6) 14 (4.1) 110 (2.7)
 No 3628 (97.4) 330 (95.9) 3958 (97.3)
Mean menopause duration (years)c 12.0 (7.7) 14.1 (7.3) 12.2 (7.7)
Bone Mineral Density T-score
 Femoral neck -0.75 (0.98) -2.27 (0.59) -0.88 (1.04)
 Total hip -0.35 (1.02) -2.04 (0.65) -0.49 (1.10)
 Lumbar spine -0.23 (1.30) -2.60 (0.88) -0.43 (1.43)
Prevalence of osteoporosis
 Definition A1 (FN, THD, LS, white female norms) - 344 (100) 344 (100)
 Definition A2 (FN, THD, white female norms) - 174 (50.6) 174 (50.6)
 Definition A3 (FN, white female norms) - 153 (44.5) 153 (44.5)
Total follow-up time (years)
 Mean 14.0 (3.8) 13.6 (4.1) 14.0 (3.9)
 Minimum 0.06 1.7 0.06
 Maximum 18.6 18.5 18.6
a
Based on Definition A1 in Supplement (FN femoral neck, THD total hip, LS lumbar spine BMD, white young female norms)
b
108 subjects BMI were recorded after their first bone mineral density
c
Based on 3012 responses and 292 responses
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Table 2
Time for 1% of participants without osteoporosis at baseline to transition to hip or 
clinical vertebral fracture, according to age group
Baseline age ranges Event N/ Group N (%) Time for 1% of participants without osteoporosis to have a hip or clinical vertebral 
fracture
Unadjusted years (95% CI) Adjusted years (95% CI)a
50 to 54 10/1029 (0.97) 12.22 (7.70, 19.40) 12.79 (8.02, 20.40)
55 to 59 18/1285 (1.40) 10.55 (6.22, 17.91) 11.72 (6.87, 19.99)
60 to 64 29/1410 (2.06) 6.05 (3.88, 9.45) 7.64 (4.82, 12.10)
a
estimated time to hip or clinical vertebral fracture, based on competing risks regression, adjusted for age group, centered T-score, race/ethnicity, 
BMI, current hormone therapy use in the model.
Estimates greater than 11 years (italicized) have questionable reliability due to excessive extrapolation required for 1% to transition to hip or 
clinical vertebral fracture.
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Table 3
Crude number of participants with hip or clinical vertebral fracture during the study 
period, according to baseline T-score (without or with osteoporosis) and clinical risk 
factors







50 to 54 10/1029 (1.0%) 3/40 (7.5%) 0.01
55 to 59 21/1285 (1.6%) 7/106 (6.6%) 0.004
60 to 64 34/1410 (2.4%) 15/198 (7.6%) <0.001
BMI
<25 21/1202 (1.8%) 15/215 (7.0%) <0.001
>=25 44/2522 (1.7%) 10/129 (7.8%) <0.001
Race/ethnicity
African-American 3/587 (0.5%) 1/19 (5.3%) 0.12
Other a 4/401 (1.0%) 3/39 (7.7%) 0.02
White 58/2736 (2.1%) 21/286 (7.3%) <0.001
Any fracture after age 55
Yes 9/193 (4.7%) 6/37 (16.2%) 0.02
No 41/2060 (2.0%) 12/201 (6.0%) 0.002
Parent fractured hipc
Yes 18/825 (2.2%) 10/101 (9.9%) <0.001
No 47/2899 (1.6%) 15/243 (6.2%) <0.001
Current smoking
Yes 7/244 (2.9%) 3/28 (10.7%) <0.001
No 58/3457 (1.7%) 22/314 (7.0%) <0.001
Oral glucocorticoids
Current 4/96 (4.2%) 2/14 (14.3%) 0.16
Past or Never 61/3628 (1.7%) 23/330 (7.0%) <0.001
Rheumatoid arthritis
Yes 3/155 (1.9%) 0/18 (0.0%) -----
No 62/3567 (1.7%) 25/326 (7.7%) <0.001
Alcohol >=3 units daily
Yes 1/27 (3.7%) 0/2 (0.0%) -----
No 64/3697 (1.7%) 25/342 (7.3%) <0.001
Hormone therapy use
Current 7/463 (1.5%) 6/52 (11.5%) <0.001
Past or Never 56/3178 (1.8%) 17/280 (6.1%) <0.001
a
Other includes all races not African-American or White
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b
P value for 2-sided Fisher exact test comparing the difference of two proportions, by baseline T-score. All hip and clinical vertebral fracture that 
occurred during follow-up were included. P value could not be calculated if one or more cells contained zeroes.
c
For parent who fractured hip or spine, P=<0.001
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Table 4
Time for 3% of participants without osteoporosis at baseline to transition to major 
osteoporotic fracture (hip, clinical spine, proximal humerus, wrist), according to age 
group
Baseline age ranges Event N/ Group N
(%)
Time for 3% of participants without osteoporosis to have a major osteoporotic fracture
Unadjusted years (95% CI) Adjusted years (95% CI)a
50-54 34/1029
(3.30)
10.11 (7.14, 14.31) 11.51 (7.95, 16.65)
55-59 61/1285
(4.75)
7.25 (4.92, 10.69) 8.95 (5.96, 13.45)
60-64 73/1410
(5.18)
6.11 (4.24, 8.79) 8.60 (5.80, 12.76)
a
estimated time to major osteoporotic fracture, based on competing risks regression, adjusted for age group, centered T-score, race/ethnicity, BMI, 
current hormone therapy use in the model.
Estimates greater than 11 years (italicized) have questionable reliability due to excessive extrapolation required for 3% to transition to fracture.
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